We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
Read MoreHide Full Article
Key Takeaways
{\"0\":\"GEHC signs agreement to acquire icometrix, an AI brain imaging analysis firm.\",\"1\":\"The acquisition aims to bolster GEHC\'s precision care strategy, particularly Alzheimer\'s treatment monitoring.\",\"2\":\"GEHC will add the first FDA-cleared CAD solution for detecting side effects of amyloid-targeting therapies.\"}
GE HealthCare (GEHC - Free Report) has recently announced plans to acquire Belgium-based icometrix, a company specializing in AI-powered brain imaging solutions, in a move designed to advance its precision care strategy and expand its neurological care portfolio. The deal underscores GE’s efforts to address the rising demand for MRI-driven insights in managing complex neurological conditions such as Alzheimer’s disease.
The deal is likely to strengthen the company’s position in the precision care, primarily in neurology. By integrating icometrix’s AI-powered insights with GEHC’s advanced imaging technologies, GEHC aims to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.
The financial terms of the deal remain undisclosed. GE HealthCare intends to fund the acquisition with cash on hand, pending customary regulatory approvals.
Likely Trend of GEHC Stock Following the News
Shares of GE HealthCare have lost 0.6% so far this year against the industry’s gain of 6.6%. The S&P 500 Index has increased 12.7% in that period.
Image Source: Zacks Investment Research
GE HealthCare’s move to acquire icometrix could be seen as a strategic long-term growth catalyst, reinforcing its positioning in the fast-expanding neurology and Alzheimer’s care markets. The deal highlights GE’s commitment to precision care and AI-driven imaging, areas expected to see rising demand. In the near term, the stock may experience muted movement given broader market conditions, but over time, the acquisition could strengthen recurring revenue streams and bolster GEHC’s competitive edge in neurological diagnostics.
More on the deal
At the core of icometrix’s offerings is its icobrain platform, which provides quantitative analysis of brain MRI scans across a spectrum of disorders, including multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury. Notably, icobrain aria stands out as the first FDA-cleared computer-aided detection and diagnosis solution for Amyloid Related Imaging Abnormalities (ARIA), a known side effect of amyloid-targeting therapies approved to treat Alzheimer’s disease. icometrix also collaborates with pharmaceutical companies to support drug development, clinical trials and real-world evidence generation
GE HealthCare plans to integrate icometrix’s solutions across its MRI platforms, streamlining workflows with its existing AI-driven technologies, including AIR x Brain, AIR Recon DL, and SONIC DL 3D. The company also intends to broaden access to icobrain aria across all vendor MRI systems, supporting radiologists and neurologists in efficiently handling growing scan volumes while maintaining high standards of care.
According to the Alzheimer’s Association, the number of adults living with Alzheimer’s is projected to double by 2050, fueled by global aging trends and broader adoption of anti-amyloid therapies. With such therapies requiring frequent neurological MRI exams to assess eligibility and monitor side effects, demand for advanced imaging and decision-support tools is expected to accelerate.
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston ScientificBSX.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio
Key Takeaways
GE HealthCare (GEHC - Free Report) has recently announced plans to acquire Belgium-based icometrix, a company specializing in AI-powered brain imaging solutions, in a move designed to advance its precision care strategy and expand its neurological care portfolio. The deal underscores GE’s efforts to address the rising demand for MRI-driven insights in managing complex neurological conditions such as Alzheimer’s disease.
The deal is likely to strengthen the company’s position in the precision care, primarily in neurology. By integrating icometrix’s AI-powered insights with GEHC’s advanced imaging technologies, GEHC aims to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.
The financial terms of the deal remain undisclosed. GE HealthCare intends to fund the acquisition with cash on hand, pending customary regulatory approvals.
Likely Trend of GEHC Stock Following the News
Shares of GE HealthCare have lost 0.6% so far this year against the industry’s gain of 6.6%. The S&P 500 Index has increased 12.7% in that period.
Image Source: Zacks Investment Research
GE HealthCare’s move to acquire icometrix could be seen as a strategic long-term growth catalyst, reinforcing its positioning in the fast-expanding neurology and Alzheimer’s care markets. The deal highlights GE’s commitment to precision care and AI-driven imaging, areas expected to see rising demand. In the near term, the stock may experience muted movement given broader market conditions, but over time, the acquisition could strengthen recurring revenue streams and bolster GEHC’s competitive edge in neurological diagnostics.
More on the deal
At the core of icometrix’s offerings is its icobrain platform, which provides quantitative analysis of brain MRI scans across a spectrum of disorders, including multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury. Notably, icobrain aria stands out as the first FDA-cleared computer-aided detection and diagnosis solution for Amyloid Related Imaging Abnormalities (ARIA), a known side effect of amyloid-targeting therapies approved to treat Alzheimer’s disease. icometrix also collaborates with pharmaceutical companies to support drug development, clinical trials and real-world evidence generation
GE HealthCare plans to integrate icometrix’s solutions across its MRI platforms, streamlining workflows with its existing AI-driven technologies, including AIR x Brain, AIR Recon DL, and SONIC DL 3D. The company also intends to broaden access to icobrain aria across all vendor MRI systems, supporting radiologists and neurologists in efficiently handling growing scan volumes while maintaining high standards of care.
According to the Alzheimer’s Association, the number of adults living with Alzheimer’s is projected to double by 2050, fueled by global aging trends and broader adoption of anti-amyloid therapies. With such therapies requiring frequent neurological MRI exams to assess eligibility and monitor side effects, demand for advanced imaging and decision-support tools is expected to accelerate.
GE HealthCare Technologies Inc. Price
GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote
GEHC’s Zacks Rank & Other Key Picks
Currently, GEHC carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. (WST - Free Report) , Medpace Holdings, Inc. (MEDP - Free Report) and Boston Scientific BSX.
West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.
Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.
Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.
Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.